AbbVie: positive opinion for UC in the UK

(CercleFinance.com) - AbbVie announced on Friday that the UK's Social Security Spending Authority has recommended that patients suffering from ulcerative colitis (UC) should have access to its Skyrizi monoclonal antibody.


The company points out that the opinion of the National Institute for Health and Care Excellence (NICE) - which decides on access to new drugs for the UK's National Health Service - concerns moderate to severe forms of this chronic inflammatory bowel disease.

According to AbbVie, some 296,000 people are affected by the disease in the UK.

This positive opinion follows the approval granted to the drug by the Medicines and Healthcare Products Regulatory Agency (MHRA), the UK health authority, two days ago.

Skyrizi (risankizumab) is a monoclonal antibody that inhibits human interleukin 23 (IL-23), a cytokine involved in inflammatory and immune responses.


Copyright (c) 2024 CercleFinance.com. All rights reserved.